Haploidentical hematopoietic stem cell transplantation with busulfan, cyclophosphamide, and fludarabine conditioning for X‐linked adrenal cerebral leukodystrophy
Pediatric Transplantation · 2024-05 · 28 (3)
DOI: 10.1111/petr.14735 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Transplantation, online erschienen am 11.04.2024. Verfasst von Yao Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Adrenoleukodystrophy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Objective
We investigated the safety and efficacy of haploidentical stem cell transplantation (SCT) in pediatric patients with X‐linked adrenoleukodystrophy (ALD).
Methods
A retrospective analysis of transplantation data from 29 cases of ALD, treated between December 2014 and April 2022, was conducted. Neurologic function scores (NFS) were assessed. The conditioning regimen was busulfan 9.6 mg/kg, cyclophosphamide 200 mg/kg, and fludarabine 90 mg/m 2 (BFC). Graft‐versus‐host disease prophylaxis consisted of anti‐human thymocyte globulin, cyclosporine A, mycophenolate mofetil, and short course of methotrexate.
Results
Among the 29 cases, 14 cases (NFS = 0) were asymptomatic, and 15 (NFS ≥ 1) were symptomatic. The median age at SCT was 8 years (range: 4–16 years); the median follow‐up time was 1058 days (range: 398–3092 days); 28 cases were father donors and 1 case was a grandfather donor. Hematopoietic reconstitution was successful in all patients, and all of them achieved complete donor chimerism at the time of engraftment. The leading cause of death was still primary disease progression ( n = 4). Survival free of major functional disabilities was 100% in asymptomatic patients versus 66.67% in the symptomatic group ( p = .018).
Conclusion
BFC regimen used in haploidentical SCT was administered safely without major transplant‐related complications even in symptomatic patients, and neurological symptoms were stabilized after SCT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking University People's Hospital, Beijing, China.
- Peking University Institute of Hematology, Beijing, China.
- National Clinical Research Center for Hematologic Disease, Beijing, China.
- Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
- First Hospital Peking University, Beijing, China.
ORCID-Profile: Xiao-Jun Huang
Zitieren
APA
Chen, Y., Xu, L. P., Zhang, X. H., Chen, H., Liu, K. Y., Qing, J., Yang, Y. L., & Huang, X. J. (2024). Haploidentical hematopoietic stem cell transplantation with busulfan, cyclophosphamide, and fludarabine conditioning for X‐linked adrenal cerebral leukodystrophy. Pediatric Transplantation, 28(3). https://doi.org/10.1111/petr.14735
Vancouver
Chen Y, Xu LP, Zhang XH, Chen H, Liu KY, Qing J, et al. Haploidentical hematopoietic stem cell transplantation with busulfan, cyclophosphamide, and fludarabine conditioning for X‐linked adrenal cerebral leukodystrophy. Pediatric Transplantation. 2024;28(3). doi:10.1111/petr.14735
BibTeX
@article{Chen2024,
author = {Chen, Yao and Xu, Lan-Ping and Zhang, Xiao-Hui and Chen, Huan and Liu, Kai-Yan and Qing, Jiong and Yang, Yan-Ling and Huang, Xiao-Jun},
title = {Haploidentical hematopoietic stem cell transplantation with busulfan, cyclophosphamide, and fludarabine conditioning for X‐linked adrenal cerebral leukodystrophy},
journal = {Pediatric Transplantation},
year = {2024},
volume = {28},
number = {3},
doi = {10.1111/petr.14735}
}
EUVIMED